NCT06938880RecruitingPhase 1/2
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors, Including Cervical Cancer, Hepatocellular Carcinoma, Neuroendocrine Tumors, and Lung Cancer
Source: ClinicalTrials.gov · Last updated 5 Jan 2026
Brief summary (registry, in English)
This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid tumors, including advanced cervical cancer, hepatocellular carcinoma, neuroendocrine cancer, and lung cancer.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 7 Apr 2025
- Start date
- 20 May 2025
- Primary completion date
- May 2027
- Lead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- NCT number
- NCT06938880
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 60
- From 20 May 2025 to the primary completion date, May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other malignancies within 5 years.
Other
- Medical history, CT scan, or MRI indicates the presence of CNS metastases.
- Any other reason deeming the participant unsuitable for the study, as judged by the investigator.
Who the study is looking for
- Fully understand this study and voluntarily sign the ICF.
- Age 18-75 years, no gender restriction.
- Patients with advanced solid tumors who have failed standard treatment or are intolerant to standard treatment, as confirmed by histopathology or cytology.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sun Yat-sen University Cancer Center Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.